Janux Therapeutics, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 10955 VISTA SORRENTO PARKWAY, SAN DIEGO, CA, 92130
Mailing Address 10955 VISTA SORRENTO PARKWAY, SAN DIEGO, CA, 92130
Phone (858) 751-4493
Fiscal Year End 1231
EIN 822289112
Financial Overview
FY2024
$1.06B
Total Assets
$366.33M
Stockholders' Equity
$-1.52
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 9, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 6, 2026 | View on SEC |
| 3 Initial insider ownership report | February 4, 2026 | View on SEC |
| 4 Insider stock transaction report | February 4, 2026 | View on SEC |
| 8-K Current report of material events | January 22, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | January 8, 2026 | View on SEC |
| 4 Insider stock transaction report | January 2, 2026 | View on SEC |
| 4 Insider stock transaction report | January 2, 2026 | View on SEC |
| 4 Insider stock transaction report | January 2, 2026 | View on SEC |
| 4 Insider stock transaction report | January 2, 2026 | View on SEC |
Insider Trading
SELL 6 insiders
8 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.